Viridian Therapeutics (VRDN) Scheduled to Post Earnings on Thursday

Viridian Therapeutics (NASDAQ:VRDNGet Rating) will release its earnings data after the market closes on Thursday, May 12th. Analysts expect Viridian Therapeutics to post earnings of ($0.92) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Viridian Therapeutics (NASDAQ:VRDNGet Rating) last issued its quarterly earnings results on Thursday, March 10th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.47). The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.75 million. During the same quarter in the prior year, the company earned ($5.31) EPS. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of VRDN stock opened at $12.09 on Thursday. The company has a market capitalization of $328.47 million, a P/E ratio of -1.57 and a beta of 1.12. The business’s 50 day moving average is $17.98 and its two-hundred day moving average is $18.75. Viridian Therapeutics has a 12-month low of $10.44 and a 12-month high of $22.00.

A number of brokerages have issued reports on VRDN. JMP Securities lowered their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “market outperform” rating on the stock in a research report on Friday, March 11th. Zacks Investment Research downgraded Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Buy” and an average price target of $32.40.

In related news, CEO Jonathan Violin sold 30,000 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $13.04, for a total transaction of $391,200.00. Following the transaction, the chief executive officer now owns 510,905 shares in the company, valued at $6,662,201.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have sold 60,000 shares of company stock worth $958,836. 8.70% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the business. Morgan Stanley acquired a new stake in Viridian Therapeutics during the second quarter worth $128,000. Bank of America Corp DE increased its stake in Viridian Therapeutics by 5,399.4% during the fourth quarter. Bank of America Corp DE now owns 9,514 shares of the company’s stock worth $188,000 after acquiring an additional 9,341 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Viridian Therapeutics during the fourth quarter worth $258,000. Citigroup Inc. acquired a new stake in Viridian Therapeutics during the fourth quarter worth $294,000. Finally, State Street Corp increased its stake in Viridian Therapeutics by 42.8% during the fourth quarter. State Street Corp now owns 34,041 shares of the company’s stock worth $673,000 after acquiring an additional 10,200 shares during the last quarter.

Viridian Therapeutics Company Profile (Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

See Also

Earnings History for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.